We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Novel Device-Based Therapies Could Overcome Limitations of Pharmacologic Therapies for Heart Failure Patients

By HospiMedica International staff writers
Posted on 11 Sep 2024
Print article
Image: The HFSA scientific statement provides an overview and update of the rapidly evolving field of device-based therapies for heart failure (Photo courtesy of JCF)
Image: The HFSA scientific statement provides an overview and update of the rapidly evolving field of device-based therapies for heart failure (Photo courtesy of JCF)

Significant strides have been made in reducing hospitalizations and improving outcomes for heart failure (HF) patients over the past decade. However, even with optimized guideline-directed medical therapy (GDMT), the residual risk remains comparable to or worse than other major cardiovascular diseases. While established medical devices like implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy (CRT) are commonly used alongside drug therapies, some high-risk patients who cannot tolerate certain medications may benefit from novel device therapies. These new device-based treatments have the potential to address the limitations of pharmacologic therapies for certain HF patients, suggesting that a combination of both approaches could be optimal for implementing GDMT.

The Heart Failure Society of America (HFSA, Rockville, MD, USA) Scientific Statement: Update on Device Based Therapies in Heart Failure, published in the Journal of Cardiac Failure (JCF), provides a comprehensive update on the rapidly evolving field of device-based therapies for HF, offering a clinical framework for integrating these technologies alongside pharmacologic treatments. The statement defines how these novel devices could help fill current gaps in HF care and outlines a pathway for incorporating FDA-approved device-based therapies in the current HF management protocol. The FDA-approved devices highlighted in the statement include cardiac contractility modulation (CCM), baroreflex activation therapy (BAT), transcatheter aortic valve replacement, mitral valve edge-to-edge repair, tricuspid valve repair, CardioMEMS pulmonary artery pressure monitoring, and the HeartMate (HM) left ventricular assist device (LVAD).

The recommended clinical pathway suggests considering these devices for patients who continue to experience New York Heart Association (NYHA) class II or above symptoms after 3-6 months of pharmacologic GDMT and CRT. The statement also calls for better systems to assess which patients are eligible for device-based therapies, as these treatments may be underutilized, especially in patients who could benefit from more than one device. Overall, the statement advocates for a personalized approach to therapy selection, combining device and pharmacologic treatments within the GDMT framework to optimize patient outcomes.

"Our consensus document defines the unmet need in chronic heart failure and the important role of device-based therapies in bridging heart failure gaps," said co-lead author Jerry D. Estep, M.D., FACC, FASE (Division Chair, Cardiovascular Medicine, Cleveland Clinic Florida). "We provide detailed information on the different categories of heart failure devices and use considerations based on associated contemporary outcome data. We hope our document will improve patient outcomes by providing a clinical framework to guide implementation of current and future FDA approved device-based therapies."

Related Links:
HFSA

New
Gold Member
X-Ray QA Meter
T3 AD Pro
Flocked Fiber Swabs
Puritan® patented HydraFlock®
New
Air/Oxygen Blender
MicroMax
New
Sterilizer
50HPO

Print article
Radcal

Channels

Surgical Techniques

view channel
Image: Researchers conducted an electric surgical procedure on a bile duct obstruction experimentally with a robotic convoy (Photo courtesy of DKFZ)

Miniature Robots Transport Instruments for Endoscopic Microsurgery Through Body

The potential applications for miniature robots in medicine are vast, ranging from targeted drug delivery to diagnostic tasks and performing surgical procedures. Researchers have already developed and... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
The Atellica VTLi Patient-side Immunoassay Analyzer, a high-sensitivity troponin I test at the bedside, delivers accurate results in just 8 minutes (Photo courtesy of Siemens Healthineers)

New 8-Minute Blood Test to Diagnose or Rule Out Heart Attack Shortens ED Stay

Emergency department overcrowding is a significant global issue that leads to increased mortality and morbidity, with chest pain being one of the most common reasons for hospital admissions.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.